Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health (RAP) receives approval to modify its US-based SARS-CoV2 clinical study
- The Institutional Review Board (IRB) approved modifications to COVID-Cough, ResApp’s COVID-19 clinical trial, to allow recruitment at in-person testing clinics
- The study aims to secure data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone, using a PCR pathology test as a reference standard
- The COVID-Cough study will recruit up to 1500 subjects, with enrolment expected to complete mid-December 2021
- ResApp Health was up 5.88 per cent, trading at 5.4 cents at 11:55 am AEDT
ResApp Health (RAP) has received approval to modify its US-based SARS-CoV2 clinical study.
The Institutional Review Board (IRB) approved modifications to COVID-Cough, ResApp’s COVID-19 clinical study, to allow recruitment at in-person testing clinics.
ResApp partnered with COVID Clinic, a network of testing sites in the US, to recruit 100 COVID-19 PCR-confirmed subjects at seven of its COVID-19 testing clinics in California.
PCR stands for polymerase chain reaction and is a test widely considered to be the most reliable way to determine whether a patient is COVID-19 positive.
The aim of the COVID-Cough pilot clinical study is to secure data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone, using a PCR pathology test as a reference standard.
“Adding the option of recruiting patients at in-person COVID-19 testing clinics will substantially increase our recruitment rate and gives us a high level of confidence that we will complete recruitment by mid-December,” CEO and Managing Director, Dr Tony Keating said.
“With our study in India also recruiting exceptionally well, we are pleased to have a growing dataset of patients from multiple continents to perform the algorithm training and validation processes needed to build an instant smartphone-based screening test for COVID-19.”
The COVID-Cough study aims to recruit up to 1500 subjects altogether, with enrolment expected to complete in mid-December 2021.
ResApp Health was up 5.88 per cent, trading at 5.4 cents at 11:55 am AEDT
